Clinical Trials

AbbVie’s risankizumab meets all primary endpoints in fourth phase 3 psoriasis trial

AbbVie’s psoriasis drug risankizumab (150 mg) has met all the primary endpoints in the two phases of a fourth pivotal phase 3 clinical trial in patients with moderate to severe plaque psoriasis.

NIH and partners commence HIV vaccine efficacy trial

The National Institutes of Health (NIH) and partners have started a clinical trial to evaluate whether an experimental HIV vaccine regimen is safe and effective in prevention of HIV infection.

Revance Therapeutics plans phase 3 program for RT002 injectable to treat cervical dystonia

Revance Therapeutics has completed its End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) and has received scientific advice from the Europe Medicines Agency (EMA) regarding DaxibotulinumtoxinA for Injection (RT002) for the treatment of cervical dystonia.

Novartis and Amgen’s erenumab succeeds in phase 3 episodic migraine trial

Novartis and Amgen’s human monoclonal antibody erenumab has succeeded in a phase 3 study by demonstrating significant and sustained efficacy in the prevention of episodic migraine.

Takeda starts phase 1 trial of Zika virus vaccine candidate

Japan's Takeda Pharmaceutical has started a phase 1 clinical trial of its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate, TAK-426.

ViiV Healthcare begins third phase III HIV trial of cabotegravir/rilpivirine regimen

ViiV Healthcare, a joint venture of GSK, Pfizer and Shionogi, has commenced a phase III study with a two-drug regimen of its long-acting, injectable cabotegravir and Janssen Sciences Ireland’s long-acting injectable rilpivirine in virally suppressed adults with HIV-1 infection.

Cancer Research UK to use Astra Zeneca’s AZD1775 in head and neck cancer trial

UK researchers are all set to launch an early-stage trial to evaluate an experimental drug from Astra Zeneca’s for improving the treatment of head and neck cancer.

Cytokinetics’ ALS treatment tirasemtiv fails to meet primary endpoint in phase 3 study

Cytokinetics has announced that international phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis (ALS) has did not meet the primary endpoint.

Summit completes initial dosing trials on Duchenne muscular dystrophy drug

Summit Therapeutics has completed the half-way stage of dosing of its Duchenne Muscular Dystrophy (DMD) candidate ezutromid in a 48-week phase 2 trial, dubbed PhaseOut DMD.